References
- Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
- Miranda R N, Glantz L K, Myint M A, Levy N, Jackson C L, Rhodes C H, et al. Stage IE non-Hodgkin's lymphoma involving the dura: a clinicopathologic study of five cases. Arch Pathol Lab Med 1996; 120: 254–260
- Kumar S, Kumar D, Kaldjian E P, Bauserman S, Raffeld M, Jaffe E S. Primary low-grade B-cell lymphoma of the dura: a mucosa associated lymphoid tissue-type lymphoma. Am J Surg Pathol 1997; 21: 81–87
- George A C, Ozsahin M, Janzer R, Agassis S, Meuli R, Baur A S, et al. Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report one case and review of the literature. Bull Cancer 2005; 92: E51–E56
- Tu P, Giannini C, Judkins A R, Schwalb J M, Burack R, O-Neill B P, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005; 23: 5718–5727
- Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
- Remstein E D, James C D, Kurtin P J. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000; 156: 1183–1188
- Yonezumi M, Suzuki R, Suzuki H, Yoshino T, Oshima K, Hosokawa Y, et al. Detection of API2-MALT1 chimaeric gene in extranodal and nodal marginal zone B-cell lymphoma by reverse transcription polymerase chain reaction (PCR) and genomic long and accurate PCR analyses. Br J Haematol 2001; 115: 588–594
- Conconi A, Martinelli G, Thiéblemont C, Ferreri A, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 15: 2741–2745
- Martinelli G, Laszlo D, Ferreri A, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979–1983
- Davis T A, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy or re-treatment. J Clin Oncol 2000; 18: 3135–3140
- Haidar J H, Shamseddine A, Salem Z, Abou Mrad Y, Nasr M R, Zaatari G, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003; 70: 330–332
- Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106: 571–572
- Davis T A, Czerwinski D K, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611–615
- Kennedy G A, Tey S K, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002; 119: 412–416
- Álvaro-Naranjo T, Jaén-Martinez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach M T. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol 2003; 82: 585–588